Reference centre for neuromuscular diseases and ALS of Marseille

Hôpitaux Universitaires de Marseille Timone

The ALS centre is integrated in the department for neuro-muscular diseases in the La Timone Hospital, Reference centre for neuromuscular diseases and ALS since 2003.

Hôpitaux Universitaires de Marseille Timone

It is devoted to the care of ALS patients and motor neuron diseases with a highly specialized multidisciplinary team. We regularly offer the opportunities to patients to participate to clinical trials. The clinical team has acquired an expertise in electrophysiological research and in neuroimaging. The centre is managed by Professor Shahram Attarian and Dr Annie Verschueren.

Contact
Location
Hôpital de La Timone, 265 rue Saint Pierre, 13265, Marseille

Experts

Annie Verschueren

Doctor of Neurology
Annie Verschueren
Current trials
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Active
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more